Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Impact · against what's priced in

The presentation on Brezosiran for Huntington's Disease provides pipeline updates but does not shift the valuation of ALNY. This program is separate from the primary valuation drivers—TTR volume normalization and the Alzheimer's pipeline—and is not yet priced as a material near-term catalyst.

ALNY+0.05

Not in the price yet

In context

The transcript provides technical progress on Brezosiran for Huntington's Disease, which is a distinct asset from the Alzheimer's (mivelsiran) or TTR programs that currently drive the stock's price action.